Wound-care Biotech

Kane Biotech (TSX‑V: KNE) announced a non‑brokered private placement of up to 16 million common shares at $0.05 each, seeking up to $800,000 in gross proceeds. Funds will support working capital and general corporate needs, including its revyve® wound‑care platform. Insiders may participate. Closing is expected around December 17 2025, subject to TSX Venture Exchange approval, and all shares will be subject to a four‑month‑plus‑one‑day lock‑up. The offering is not registered in the United States and cannot be sold to U.S. persons.